Skip to content

Earnings yield at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.4%-1.1pp
HRO
HarrowHROW
-2.1%-0.5pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-18%-4.7pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-15.8%-0.7pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-8.8%-22.8pp
Vera Therapeutics logo
Vera TherapeuticsVERA
-12.9%+1.8pp

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

Based on trailing twelve months.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's earnings yield?
Kodiak Sciences Inc (KOD) reported earnings yield of -9.9% in Q1 2026.
How has Kodiak Sciences Inc's earnings yield changed year-over-year?
Kodiak Sciences Inc's earnings yield increased by 92.3% year-over-year, from -129.1% to -9.9%.
What is the long-term trend for Kodiak Sciences Inc's earnings yield?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's earnings yield has grown at a 50.4% compound annual growth rate (CAGR), from -1.8% to -13.5%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.